Lanthanide IMAC Supports for Protein Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current IMAC supports for protein purification face challenges with stability, selectivity, and toxicity due to the use of metal ions like Ni2+ and Co2+, which are toxic and carcinogenic, and existing methods lack efficient ways to control ligand distance and reduce non-specific binding.

Innovation Solution

Development of IMAC supports using lanthanide ions, such as La, Ce, Nd, Sm, Eu, Gd, Dy, Ho, Er, Tm, Yb, Lu, which offer higher coordination ability, enhanced selectivity, and reduced toxicity, along with surface modification to control ligand distance and incorporate inert groups to minimize non-specific binding.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional metal ions (Ni2+, Co2+) are used in IMAC supports, then protein binding capacity is achieved, but toxicity and carcinogenicity increase

Engineering Contradiction:
Improveprotein binding capacityVSAvoidtoxicity and carcinogenicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the metal ion parameter from traditional Ni2+/Co2+ to lanthanide ions (La3+, Ce3+, Nd3+, Sm3+, Eu3+, Gd3+, Dy3+, Ho3+, Er3+, Tm3+, Yb3+, Lu3+). This parameter substitution maintains protein binding capacity through coordination chemistry while eliminating the toxic effects associated with transition metals, as lanthanides exhibit lower toxicity and are not carcinogenic.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent converts the previously harmful effect of metal ion toxicity into a benefit by selecting lanthanide ions that provide comparable or enhanced coordination ability for protein binding while being non-toxic and non-carcinogenic. The high coordination ability of lanthanides, which was previously unused, becomes the advantageous feature of the system.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If ligand density is increased to improve binding capacity, then more proteins can be bound, but non-specific binding increases

Engineering Contradiction:
Improvebinding capacityVSAvoidselectivity
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

The patent applies local quality control by modifying the support surface with inert groups in specific locations between the chelating ligands. This creates zones of high ligand density for binding while interspersing inert zones that prevent non-specific interactions, thereby maintaining selectivity even at higher overall ligand densities.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent creates a composite surface structure combining chelating ligands (for specific metal-protein binding) with inert groups (for non-specific binding prevention). This composite approach allows the system to achieve high binding capacity through increased ligand density while the inert components maintain selectivity by blocking non-specific adsorption sites.

Inventive Principle:
Principle #40Composite materials

3Ease of manufacture

If ligand distance is not controlled, then simpler support preparation is achieved, but binding selectivity decreases

Engineering Contradiction:
Improvesupport preparation simplicityVSAvoidbinding selectivity
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent applies preliminary action by pre-designing and incorporating spacers or rigid linkers into the ligand structure before attachment to the support. This pre-established geometric framework ensures uniform ligand spacing and optimal distance from the metal ion coordination site, thereby achieving high binding selectivity without complicating the overall support preparation process.

Inventive Principle:
Principle #10Preliminary action

4Productivity

If traditional IMAC supports are used, then protein purification is achieved, but stability and selectivity are limited

Engineering Contradiction:
Improveprotein purification efficiencyVSAvoidstability and selectivity
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent changes multiple parameters simultaneously: metal ion type (to lanthanides with higher coordination numbers and stability constants), ligand structure (with optimized spacing and inert groups), and support chemistry. These parameter changes collectively enhance both the stability of the metal-ligand-protein complex and the selectivity of binding, thereby improving overall purification efficiency and reliability.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of lanthanide-based IMAC supports provides increased stability, selectivity, and reduced toxicity for protein binding and separation, allowing for sensitive protein binding and elution monitoring through optical changes, while minimizing environmental impact.

Implementation Method 1

Owing to chelate formation metal ions are strongly bound to the matrix

Methodology Applied
Scientific EffectChelate formation: Chemical Bonding

Implementation Method 2

Proteins can associate to the matrix through histidine, cysteine or tryptophan residing on their surface and having affinity to metal chelates

Methodology Applied
Scientific EffectMetal affinity binding: Chemical Bonding

Implementation Method 3

allowing for sensitive protein binding and elution monitoring through optical changes

Methodology Applied
Scientific EffectOptical changes:

Data Source

PatentEP2943501B1Compositions for binding and separating of proteins
Publication Date: 2019.06.26 FERMENTIA MIKROBIOLOGIAI KFT
  • EP2943501B1 patent drawingFigure 1
  • EP2943501B1 patent drawingFigure 2A~2C
  • EP2943501B1 patent drawingFigure 3A~6

AI summary

A composition for binding and separating proteins characterized by the general formula (II) wherein R1 is a hydrophobic group of small size, preferably hydrogen, or C1C8 straight chain or branched alkyl, or C2-C8 straight chain or branched alkenyl or alkynyl, C6-G8 aryl or aralkyl or cycloalkyl group; or alkoxy group, preferably methoxy or ethoxy group; or acyloxy group, preferably acetyloxy group; or chlorine, R2 is R1 or a hydrophobic group of small size, preferably hydrogen, or C1C8 straight chain or branched alkyl, or C2-C8 straight chain or branched alkenyl or alkynyl, C6-C8 aryl or aralkyl or cycloalkyl group; or alkoxy group, preferably methoxy- or ethoxy group; or acyloxy group, preferably acetyloxy group; or chlorine different form R1, R3 is R2 or a non-reactive group which contains straight chain, branched or cyclic structures formed by 2 - 30 covalently connected carbon, oxygen, sulfur, fluorine, chlorine, bromine or iodine atoms, symbol = represents one, two or three covalent single bonds between the Si atoms and the surface of the support, in case of one covalent bond, two of the R1- R3 groups are attached to the given Si atom; in case of two covalent bonds, one of the R1- R3 groups is attached to the given Si atom; in case of three covalent bonds, none of the groups R1 - R3 are attached to the given Si atom, A is an atom or group of atoms containing a non-bonding pair of electrons, preferably NH, NR3, S, O, L is a straight, branched or cyclic structure connecting Si atoms and the A moiety comprising 2 - 22 carbon, sulfur or nitrogen atoms covalently connected to each other, x is a number and 0 >x> 1, m is an integer and m = 0, 1 or 2.